Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2011
Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice
Francesco Trotta, Hubert G M Leufkens, Jan H M Schellens, et al.
European Journal of Clinical Pharmacology
|
September 18, 2008
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease
Giovanni Tafuri, Francesco Trotta, Hubert G M Leufkens, et al.
Recenti Progressi in Medicina
|
February 25, 2020
[Establishing the value of new drugs in Italy.]
Federico Villa, Claudio Jommi, Gianluca Altamura, et al.
Health Policy (Amsterdam, Netherlands)
|
May 18, 2019
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency
Federico Villa, Michaela Tutone, Gianluca Altamura, et al.
Frontiers in Medicine
|
March 7, 2022
Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019
Federico Villa, Aurora Di Filippo, Andrea Pierantozzi, et al.
International Clinical Psychopharmacology
|
October 3, 2006
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders
Alessandro Assisi, Rita Banzi, Carmela Buonocore, et al.
British Journal of Clinical Pharmacology
|
November 23, 2017
Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans
Leroy R A Lepelaars, Francesca Renda, Luca Pani, et al.
British Journal of Clinical Pharmacology
|
June 2, 2016
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice
Giovanni Tafuri, Margherita Pagnini, Jane Moseley, et al.
Drug Discovery Today
|
April 29, 2020
Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations
Rick A Vreman, Angela S de Ruijter, Anna Zawada, et al.
International Journal of Technology Assessment in Health Care
|
April 23, 2020
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Giovanni Tafuri, Chantal Bélorgey, Carlo Favaretti, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2011
Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice
Francesco Trotta, Hubert G M Leufkens, Jan H M Schellens, et al.
European Journal of Clinical Pharmacology
|
September 18, 2008
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease
Giovanni Tafuri, Francesco Trotta, Hubert G M Leufkens, et al.
Recenti Progressi in Medicina
|
February 25, 2020
[Establishing the value of new drugs in Italy.]
Federico Villa, Claudio Jommi, Gianluca Altamura, et al.
Health Policy (Amsterdam, Netherlands)
|
May 18, 2019
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency
Federico Villa, Michaela Tutone, Gianluca Altamura, et al.
Frontiers in Medicine
|
March 7, 2022
Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019
Federico Villa, Aurora Di Filippo, Andrea Pierantozzi, et al.
International Clinical Psychopharmacology
|
October 3, 2006
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders
Alessandro Assisi, Rita Banzi, Carmela Buonocore, et al.
British Journal of Clinical Pharmacology
|
November 23, 2017
Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans
Leroy R A Lepelaars, Francesca Renda, Luca Pani, et al.
British Journal of Clinical Pharmacology
|
June 2, 2016
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice
Giovanni Tafuri, Margherita Pagnini, Jane Moseley, et al.
Drug Discovery Today
|
April 29, 2020
Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations
Rick A Vreman, Angela S de Ruijter, Anna Zawada, et al.
International Journal of Technology Assessment in Health Care
|
April 23, 2020
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Giovanni Tafuri, Chantal Bélorgey, Carlo Favaretti, et al.
Page
of 3